Amivantamab price

Amivantamab (Amivantamab) is an innovative biologic drug used to treat a specific type of lung cancer, non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. It was developed to meet the needs of patients whose tumors have progressed despite treatment with other treatment modalities, such as EGFR tyrosine kinase inhibitors (TKIs).

Evantuzumab is not yet available in China, so patients cannot purchase it domestically and need to purchase it through foreign channels. There are only European versions of original drugs available abroad, and the price is relatively high, around 20,000 yuan.

Evantumumab is a new antibody drug that fights tumor growth through a dual-targeting mechanism. It has a unique dual role, which can inhibit EGFR mutations and block the MET signaling pathway, thereby slowing or inhibiting tumor growth. This revolutionary mechanism can reduce tumor resistance to treatment and provide patients with more treatment opportunities.

Clinical trials have shown that evantumumab has achieved significant therapeutic effects in some patients with EGFR mutated lung cancer, including those who have previously developed resistance to TKI treatment. It also demonstrated a favorable safety and tolerability profile, making treatment more acceptable to patients.

The development of evantumumab represents an important breakthrough in the field of precision cancer treatment, providing a new treatment option for EGFRmutatedNSCLC patients. However, patients should consult their doctor before receiving this medication to learn about its suitability as well as possible side effects and risks.

In summary, evantumumab is a potentially important drug that represents hope and an opportunity for therapeutic advancement for patients with EGFRmutated NSCLC, offering new prospects for improving their quality of life and survival.